同种异体PRP储备库的构建与临床应用：突破个体化局限的再生医学新策略*

doi:10.3969/j.issn.1671-2587.2026.04.002

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (4): 467-475.DOI: 10.3969/j.issn.1671-2587.2026.04.002

同种异体PRP储备库的构建与临床应用：突破个体化局限的再生医学新策略^*

王文婷, 吴粉毅, 党娥, 刘涛, 尹文

空军军医大学西京医院输血科,陕西西安 710032

收稿日期:2026-07-07 出版日期:2026-08-20 发布日期:2026-08-26
通讯作者: 尹文,主要从事血细胞保存损伤机制、干细胞与细胞治疗,（E-mail）yinwen@fmmu.edu.cn。
作者简介:王文婷,主要从事免疫血液学检验、血液治疗与血细胞保护相关研究,（E-mail）wangwenting1106@163.com。
基金资助:
^*本课题受空军军医大学西京医院助推专项（No.XJZT26JS34）、医务人员新技术新业务（No.2025XJSM04）资助

Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations

WANG Wenting, WU Fenyi, DANG E, LIU Tao, YIN Wen

Department of Transfusion Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032

Received:2026-07-07 Online:2026-08-20 Published:2026-08-26

摘要/Abstract

摘要： 富血小板血浆（PRP）因其富含多种生长因子,在组织修复与再生医学领域展现出显著疗效。然而,自体PRP的广泛应用受限于个体差异、制备时间延迟及供体并发症等瓶颈,制约其临床推广。构建标准化同种异体PRP（allogeneic platelet-rich plasma, al-PRP）储备库,可实现制剂即用型、批间均一化供给,是突破自体PRP临床应用困境的核心创新策略。本文系统阐述al-PRP储备库的标准化构建理念、规范化制备与全链条质量控制体系,重点聚焦人源al-PRP基础研究与临床证据,深入探讨al-PRP在骨关节炎、慢性难愈性创面及肌腱韧带损伤等再生医学场景的临床价值。同时,结合我国细胞治疗与血液制品监管法规,剖析储备库建设的合规路径、技术瓶颈、伦理规范及行业发展痛点,旨在为al-PRP储备库的临床转化、标准化落地及产业化发展提供理论依据与实践参考。

关键词: 同种异体富血小板血浆, 再生医学, 生长因子, 质量控制, 临床转化

Abstract: Platelet-rich plasma (PRP) has demonstrated substantial therapeutic efficacy in tissue repair and regenerative medicine, owing to its abundant reservoir of growth factors. However, the widespread clinical application of autologous PRP is hampered by inherent limitations, including interindividual variability, time-consuming preparation, and donor-site complications that impede its broader adoption. The establishment of a standardized allogeneic PRP (al-PRP) bank, which enables ready-to-use availability and batch-to-batch consistency, represents a pivotal innovative strategy to overcome the clinical barriers associated with autologous PRP. This review systematically elaborates the conceptual framework for constructing a standardized al-PRP bank, covering standardized manufacturing procedures and a whole-chain quality control system. Emphasis is placed on fundamental research and clinical evidence derived from human-derived al-PRP, with an in-depth discussion of its clinical value in regenerative scenarios, including osteoarthritis, chronic non-healing wounds, and tendon and ligament injuries. We analyze the regulatory landscape in China pertaining to cell-based therapies and blood products, addressing compliance pathways, technical bottlenecks, ethical considerations, and industry-wide challenges. This review aims to provide a theoretical foundation and practical reference for the clinical translation, standardized implementation, and industrial-scale development of al-PRP banks.

Key words: Allogeneic platelet-rich plasma, Regenerative medicine, Growth factors, Quality control, Clinical translation

中图分类号:

R318
R457.1

王文婷, 吴粉毅, 党娥, 刘涛, 尹文. 同种异体PRP储备库的构建与临床应用：突破个体化局限的再生医学新策略^*[J]. 临床输血与检验, 2026, 28(4): 467-475.

WANG Wenting, WU Fenyi, DANG E, LIU Tao, YIN Wen. Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(4): 467-475.

参考文献

[1] Rath M,Spinnen J,Kuhrt L D,et al.Platelet-rich plasma -A comprehensive review of isolation,activation,and application[J]. Acta Biomater,2025,204:52-75.
[2] Anitua E,Padilla S.Tinkering with blood: optimizing the coagulation system for therapeutic purposes[J]. Bioengineering (Basel),2025,12(12):1301.
[3] Gupta A,Migliorini F,Maffulli N.Management of rotator cuff injuries using allogenic platelet-rich plasma[J]. J Orthop Surg Res,2024,19(1):165.
[4] Gupta A,Aratikatla A,Martin S M.Allogenic platelet-rich plasma for the treatment of adhesive capsulitis[J]. Cureus,2023,15(10):e47491.
[5] Romano V,Bignotti S,Forbice E,et al.Allogeneic solid platelet-rich plasma for persistent epithelial neurotrophic defects: a protocol and pilot study[J]. Cornea,2023, 42(4):498-506.
[6] Tang Y K,Li Y S,Chen H W,et al.Application of cord blood-derived platelet-rich plasma in the treatment of diseases[J]. J Int Med Res,2024,52(7):3000605241263729.
[7] Dohan Ehrenfest D M,Rasmusson L,Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol,2009,27(3): 158-167.
[8] 单桂秋, 施琳颖, 李艳辉, 等. 自体富血小板血浆制备技术专家共识[J]. 中国输血杂志,2021,34(7):677-683.
[9] Croisé B,Paré A,Joly A,et al.Optimized centrifugation preparation of the platelet rich plasma: Literature review[J]. J Stomatol Oral Maxillofac Surg,2020,121(2): 150-154.
[10] Giannotti L,Di Chiara Stanca B,Spedicato F,et al. Progress in regenerative medicine: exploring autologous platelet concentrates and their clinical applications[J]. Genes,2023,14(9):1669.
[11] Gagliano C,Foti R,Zeppieri M,et al.Umbilical cord blood platelet lysate eyedrops for the treatment of severe ocular surface disorders in graft vs. host disease patients: clinical study[J]. Life (Basel),2024,14(10):1268.
[12] Jo C H,Roh Y H,Kim J E,et al.Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation[J]. J Oral Implantol,2013, 39(5):525-532.
[13] da Silva L Q,Montalvão S A L,Justo-Junior A D S,et al. Platelet-rich plasma lyophilization enables growth factor preservation and functionality when compared with fresh platelet-rich plasma[J]. Regen Med,2018,13(7):775-784.
[14] Saqlain N,Mazher N,Fateen T,et al.Comparison of single and double centrifugation methods for preparation of Platelet-Rich Plasma (PRP)[J]. Pak J Med Sci,2023, 39(3):634-637.
[15] Panero A J,Warrick A E,Nakagawa H,et al.Comparing biologic factor composition of birth tissue-derived allografts and platelet-rich plasma[J]. Cureus,2025,17(8): e90259.
[16] Nakhaei Amroodi M,Mokhtari K,Tabrizian P.Platelet-rich plasma in orthopedics: unraveling cellular mechanisms,therapeutic potential,and limitations[J]. Galen Med J,2025,14:e3883.
[17] Zhang G M,Song Y N,Zhuang T S,et al.Clinical application and research progress of platelet-rich plasma[J]. Hematology,2025,30(1):2549159.
[18] Zhang Z Y,Huang A W,Fan J J,et al.The potential use of allogeneic platelet-rich plasma for large bone defect treatment: immunogenicity and defect healing efficacy[J]. Cell Transplant,2013,22(1):175-187.
[19] Qin H J,Yang H,Wang J,et al.Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment[J]. Front Endocrinol,2025,16:1694691.
[20] Hassan N H,Ahmad R E,Kamarul T,et al.Allogenic platelet-rich plasma for treating cartilage injury: a systematic review of the evidence on the basic sciences for potential future applications[J]. Cells Tissues Organs,2024,213(4):338-355.
[21] Suelzu C M,Conti V,Khalidy Y,et al.Xenobiotic-free medium guarantees expansion of adipose tissue-derived canine mesenchymal stem cells both in 3D fibrin-based matrices and in 2D plastic surface cultures[J]. Cells,2020, 9(12):2578.
[22] Catarino J,Carvalho P,Santos S,et al.Treatment of canine osteoarthritis with allogeneic platelet-rich plasma: review of five cases[J]. Open Vet J,2020,10(2):226-231.
[23] Van Reusel Y,Broeckx S Y,Carolo A,et al. Composition of allogeneic equine orthobiologics and their repeated intra-articular administrations[J]. Equine Vet J,2026:evj. 70196.
[24] Zhu X H,Zhao L Y,Riva N,et al.Allogeneic platelet-rich plasma for knee osteoarthritis in patients with primary immune thrombocytopenia: A randomized clinical trial[J]. iScience,2024,27(5):109664.
[25] Sánchez M,Guadilla J,Jorquera C,et al.Intra-articular injections of allogeneic platelet-rich plasma from responder patients for the treatment of knee osteoarthritis: a pilot and feasibility clinical trial[J]. CARTILAGE,2025: 19476035251355522.
[26] Caiaffa V,Ippolito F,Abate A,et al.Allogenic platelet concentrates from umbilical cord blood for knee osteoarthritis: preliminary results[J]. Med Glas,2021, 18(1):260-266.
[27] Araya N,Miyatake K,Tsuji K,et al.Intra-articular injection of pure platelet-rich plasma is the most effective treatment for joint pain by modulating synovial inflammation and calcitonin gene-related peptide expression in a rat arthritis model[J]. Am J Sports Med, 2020,48(8):2004-2012.
[28] Huang G S,Peng Y J,Hwang D W,et al.Assessment of the efficacy of intra-articular platelet rich plasma treatment in an ACLT experimental model by dynamic contrast enhancement MRI of knee subchondral bone marrow and MRI T2 measurement of articular cartilage[J]. Osteoarthr Cartil,2021,29(5):718-727.
[29] Del Amo C,Perez-Valle A,Atilano L,et al.Unraveling the signaling secretome of platelet-rich plasma: towards a better understanding of its therapeutic potential in knee osteoarthritis[J]. J Clin Med,2022,11(3):473.
[30] Wang L L,Zhao L T,Shen L W,et al.Comparison of the effects of autologous and allogeneic purified platelet-rich plasma on cartilage damage in a rabbit model of knee osteoarthritis[J]. Front Surg,2022,9:911468.
[31] Giusti S,Cerulli S,Giacinto E,et al.Is umbilical cord-derived platelet-rich plasma a valid alternative to conventional orthobiologics post-knee arthroscopy?[J]. Adv Orthop,2025,2025:8026214.
[32] 巩蜜蜜,汪海宁,吴磊,等. 同种异体富血小板血浆用于慢性难愈性创面的临床研究[J]. 临床输血与检验,2023, 25(3):368-374.
[33] Li Y L,Wang X T,Li Y C,et al.Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials[J]. Sci Rep,2024,14(1):25209.
[34] He M,Chen T Y,Lv Y H,et al.The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges[J]. Front Bioeng Biotechnol,2022,10:993436.
[35] 王淑君. 异体富血小板血浆治疗难治性创面的临床及基础研究[D]. 南京:东南大学,2023.
[36] 刘凌,卢黎琦,刘曹毅,等. 同种异体富血小板血浆在创面修复中的应用及展望[J]. 中国输血杂志,2024,37(4):482-490.
[37] Zhu X H,Zhao L Y,Liu A,et al.Efficacy of intra-articular injection of allogeneic platelet-rich plasma for knee osteoarthritis combined with hematologic blood dyscrasias with platelet dysfunction: protocol of a randomized,double-blind,placebo-controlled trial[J]. BMC Musculoskelet Disord,2022,23(1):1095.
[38] Serteyn D,Graide H,Ceusters J,et al.Sequential application of autologous platelet rich plasma and muscle-derived mesenchymal stem cells for acute tendon injuries in horses: early clinical and ultrasonographic outcomes in a randomized,double-blind controlled study[J]. Animals,2026,16(6):940.
[39] Wu W S,Chen L R,Chen K H.Platelet-rich plasma (PRP): molecular mechanisms,actions and clinical applications in human body[J]. Int J Mol Sci,2025,26(21):10804.
[40] Sclafani A P,Azzi J.Platelet preparations for use in facial rejuvenation and wound healing: a critical review of current literature[J]. Aesthetic Plast Surg,2015,39(4): 495-505.
[41] Chatha P K,Pellakuru S R,Botchu R,et al.Orthobiologics: current evidence and what lies beyond the horizon?[J]. Semin Musculoskelet Radiol,2026,30(1): 14-27.
[42] Acebes-Huerta A,Martínez-Botía P,Carbajo-Argüelles G,et al.Characterization of the molecular composition and in vitro regenerative capacity of platelet-based bioproducts and related subfractions[J]. Acta Biomater, 2024,177:132-147.
[43] Mohseni R,Mahdavi Sharif P,Khosravi A,et al. The application of umbilical cord blood-derived platelet gel for skin ulcers associated with chronic graft-versus-host disease in pediatrics: a randomized trial[J]. Transplant Cell Ther,2024,30(7):694.e1-694.e10.
[44] Tomac A A,Coșarcă C M,Trâmbițaș C,et al.Platelet-rich plasma in the management of diabetic foot ulcers (Review)[J]. Biomed Rep,2026,24(6):69.

同种异体PRP储备库的构建与临床应用：突破个体化局限的再生医学新策略^*

Construction and Clinical Application of Allogeneic PRP Banks: A Novel Regenerative Medicine Strategy to Overcome Individualized Limitations

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	王璐璐, 陈利达, 芦宏凯, 刘希曦, 郭伟洁, 高欣, 曹永彤. 流式荧光法PRA检测中降低非特异性本底的组合预处理研究^*[J]. 临床输血与检验, 2026, 28(4): 539-545.
[2]	马一鸣, 马超, 张勇刚, 李小飞. 输血（医学）科主导细胞与基因治疗院内质量控制的逻辑基础与实现路径^*[J]. 临床输血与检验, 2026, 28(3): 312-316.
[3]	长三角一体化临床输血质量控制与管理联合体, 上海市临床输血质量控制中心, 上海市社会医疗机构协会输血专业委员会, 上海市医学会输血专科分会, 上海市医师协会输血科医师分会. 临床输血全流程清单式质量管理专家共识[J]. 临床输血与检验, 2026, 28(2): 153-161.
[4]	王辉, 赵琴, 陈立力, 黄永莉, 张进进, 邢颜超. HPL-CS温敏凝胶促高原糖尿病大鼠难愈性创面愈合的研究^*[J]. 临床输血与检验, 2025, 27(4): 433-441.
[5]	王淑君, 李兆杰, 杨奕, 栾建凤. 血小板衍生制品促进创面愈合的研究进展^*[J]. 临床输血与检验, 2024, 26(6): 825-834.
[6]	郝梦玲, 汤龙海, 金一鸣, 肖琦, 方敏. 血浆制品中凝血因子Ⅷ含量及抽检结果的影响因素分析^*[J]. 临床输血与检验, 2024, 26(5): 630-637.
[7]	赵子悦, 黄韦华, 查占山. 富血小板血浆与间充质干细胞的联合应用在再生医学中的前景^*[J]. 临床输血与检验, 2024, 26(3): 420-426.
[8]	中国输血协会临床输血管理学专业委员会. 术前深度单采自体红细胞和/或血小板储血技术应用中国专家共识[J]. 临床输血与检验, 2024, 26(2): 145-155.
[9]	肖军, 雷慧芬, 李翠莹. 血小板裂解液与血小板凝胶生长因子谱的表达差异研究^*[J]. 临床输血与检验, 2023, 25(4): 450-455.
[10]	聂志扬, 赵学彬, 马婉茹, 李淑萍. 2020年全国临床用血质量控制指标调研分析[J]. 临床输血与检验, 2023, 25(4): 514-517.
[11]	治疗性单采过程管理与质量控制专家共识编写组. 治疗性单采过程管理与质量控制专家共识[J]. 临床输血与检验, 2023, 25(1): 1-9.
[12]	钟杰, 茹雪, 王安凤. 血清IL-6、FGF-23水平与慢性肾衰竭血透患者蛋白质-能量消耗发生的关系[J]. 临床输血与检验, 2022, 24(6): 777-784.
[13]	刘纪君, 李雪蕾, 陈红波, 韩保良, 邵坤, 赵雪芬, 刘静, 晏艳, 许晓红. 孕早期PlGF联合PAPP-A、MAP、UtPI预测子痫前期的临床应用研究^*[J]. 临床输血与检验, 2022, 24(4): 476-481.
[14]	杨慕坤, 王子君, 崔广霞, 陈麟凤, 白文佩. 富血小板纤维蛋白对宫腔粘连创面修复的影响研究^*[J]. 临床输血与检验, 2022, 24(3): 363-368.
[15]	罗开云, 王淑君, 毛平平, 孙杨子, 齐清, 栾建凤. 不同保存方式对PRP相关生长因子影响的研究*[J]. 临床输血与检验, 2022, 24(1): 70-73.